Trial-Reported Endpoints by Phase Trial Lancet 2021 Phase 2 Duration 26 weeks Population Overweight/obese, no T2D (n=706) Mean Weight Loss 10.8% at 4.5 mg vs 3.0% placebo Trial Lancet 2023 Phase 2 Duration 32 weeks Population T2D + obesity (n=92) Mean Weight Loss 8.1% cagrilintide alone
Cartilage & Joint Protection Because DSIP is often studied for sleep regulation , it is natural to compare it with melatonin , the most widely used sleep supplement: AOD-9604 demonstrated chondroprotective effects in models of cartilage degradation. May reduce proteoglycan loss and support collagen maintenance
The trial is expected to begin late next year and is projected to last approximately two to three years
Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S: A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis
BPC-157 was among them (source)
intensive care needs to be taken with any type of sterile water used for reconstitution
